Lymphoma Therapeutics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation) By End User (Hospitals, Cancer Specialty Clinics, Ambulatory Treatment Centers) and  Region Forecast 2020-2031

Lymphoma Therapeutics Market size was valued at US$ 18,136.2 million in 2024 and is projected to reach US$ 31,487.4 million by 2031 at a CAGR of 8.2% from 2025-2031.  Lymphoma treatments consist of a range of medical treatments chemotherapy, targeted treatment, immunotherapy, and stem cell transplant to cure a range of lymphomas, a lymph system cancer. The demand for lymphoma treatments is expanding as a result of a range of strong drivers. Rising incidence rates, especially among the elderly, are driving demand, as are enhanced diagnostic technologies that detect instances earlier.

Innovations in targeted therapy and immunotherapy, including CAR-T and monoclonal antibodies, have transformed treatment regimens, offering improved survival and reduced side effects. Robust insurance coverage within healthcare systems also supports uptake. But the market is not without its difficulties. The cost of new medications might constrain access, especially where there is no reimbursement. Complexity in treatment, such as the need for specialist staff and equipment, presents logistical obstacles. Moreover, tumor heterogeneity complicates personalized treatment protocols, and resistance or relapse is seen in a few instances. All these influence a market that is marked by advance and caution.

Facts & Figures

• In the United States, lymphoma accounts for about 5% of all cancers, with Non-Hodgkin lymphoma (NHL) being more common than Hodgkin lymphoma (HL).
• In 2022, approximately 8,540 people in the US were diagnosed with HL.
• The incidence rate for HL has been declining by about 1% per year since the mid-2000s.
• Most cases of HL are chemosensitive, and the overall survival rate is around 86%.
• In 2024, it's estimated that 21,050 people in the US will die from lymphoma, with 20,140 of those deaths attributed to NHL.
• The age-adjusted incidence rates for NHL in India are 2.9/100,000 for men and 1.5/100,000 for women, which is lower than in Western Europe or North America.
• About 80,620 people will be diagnosed with NHL in the US in 2024, according to the American Cancer Society.

Key Developments

• In February 2025, Novartis received expanded approval for its CAR-T therapy to include mantle cell lymphoma, enhancing its footprint in blood cancer treatment and offering new curative intent options.
• In January 2025, Roche initiated global trials of its BTK inhibitor combined with anti-CD19 immunotherapy, aimed at improving outcomes in marginal zone lymphoma and chronic lymphocytic variants.
• In September 2024, Gilead’s Kite Pharma launched a next-generation CAR-T with improved safety profile and shorter manufacturing time in the U.S., offering faster treatment timelines for patients.
• In June 2024, BMS announced positive Phase III data for a bispecific antibody targeting CD20 and CD3 in relapsed or refractory large B-cell lymphoma, marking a potential off-the-shelf alternative to CAR-T.

Lymphoma Therapeutics Market Segmentation

Based on the treatment type

• Chemotherapy
• Targeted Therapy (BTK inhibitors, PI3K inhibitors, others)
• Immunotherapy (CAR-T, bispecific antibodies, monoclonal antibodies)
• Stem Cell Transplantation

Immunotherapy is revolutionizing the management of lymphoma. CAR-T cell therapy, which genetically modifies a patient's immune cells to target cancer directly, induces deep and even long-term remission in some aggressive lymphomas. Bispecific antibodies enable the immune system to target T cells and tumor cells simultaneously offering off-the-shelf convenience with encouraging results. Monoclonal antibodies continue to offer a pillar, targeting CD20 and CD19 antigens with better safety profiles. These therapies are post-chemotherapy or at relapse. While extremely effective, these have to be monitored closely for their side effects such as cytokine release or neurotoxicity. With more availability and mass production, immunotherapy will be the platform of choice for all lymphomas.

Based on the end user

• Hospitals
• Cancer Specialty Clinics
• Ambulatory Treatment Centers

Oncology specialty clinics are dedicated solely to the care of oncology, with direct access to specialist therapy, clinical trials, and supportive care that form the backbone of lymphoma treatment. Such centers are generally at the forefront in providing CAR-T and bispecific antibody regimens that entail specialist nursing and observation. They have multidisciplinary teams of oncologists, pharmacists, nurses, and counselors that provide streamlined patient journeys from diagnosis to follow-up. They also have molecular diagnostic testing laboratories and sample biobanks that can facilitate precision-driven treatment decision. They are supported by strong patient volumes and referral networks and the ability to deliver advanced therapies and collect real-world outcomes with high efficiency, which is a particular strength. Their commitment to personalized care and associated services renders them the center for driving lymphoma outcomes.